Read, understand and consent to the blog's disclaimer here before proceeding to read the article
The above could be Mylan/Nacto's copaxone characterization IP(guess). I see Nacto had some collaboration in the past with ScinoPharm, the assignee on this patent. Hence my guess. Of course, I could be wrong.
The difference b/w MNTA's analysis and the above, appears to be: MNTA has found a proxy signature "pyro-gluco" content and they use that for testing the sameness/equivalence. This may lend itself to testing in commercial manufacturing setting. However, the above IP indicates detailed MS analysis.
MNTA's copaxone characterization IP
Separately, a new Copaxone ANDA has been filed by Synthon.
If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.